Novo Nordisk Semaglutide Cut Cardio Risks by 14% in Diabetics: Study
Report: novo-nordisk a/s weight loss drug Ozempic's 'sister drug' significantly reduces heart disease risk in experiments.
Patients with type 2 diabetes and a history of heart disease, chronic kidney disease, etc., have a 14% lower probability of experiencing cardiovascular events after taking Rybelsus compared to patients taking a placebo.
Studies show that novo-nordisk a/s (NVO.US) oral semaglutide reduces the risk of heart disease.
Rybelsus, an oral semaglutide under novo-nordisk a/s, reduced the risk of heart attacks and strokes in a large study, potentially leading to wider use of the medication.
Wegovy Maker Novo Nordisk's Oral Diabetes Pill Cuts Heart Attacks, Stroke Events By 14%
Novo Nordisk Says Its Rybelsus Oral Semaglutide Reduces Risk of Major Adverse Cardiovascular Events
Catalent's Maselli to Continue as CEO Post Novo Holdings Deal Close
Novo Nordisk's Oral Cardiovascular Drug Trial Achieves Primary Objective
Novo Nordisk Announced SOUL Cardiovascular Outcomes Trial Achieved Its Primary Objective By Demonstrating A Statistically Significant And Superior Reduction In MACE Of 14% For People Treated With Oral Semaglutide Vs Placebo
'FDA Won't Take Action Against GLP-1 Compounders As It Rethinks Tirzepatide Shortage' - Endpoints News
European Equities Close Mostly Higher in Friday Trading; Novo Nordisk's Catalent Acquisition Faces Roadblock
Viking Stock Rises 29% in Three Months: Time to Buy, Hold or Sell?
Weight loss drug expansion plan faces obstacles! Consumer groups in the USA demand the FTC to block the shareholders of novo-nordisk a/s from acquiring catalent.
On Thursday, consumer groups and two large unions in the usa urged the Federal Trade Commission (FTC) to block the acquisition contract of drug manufacturer catalent by novo-nordisk a/s shareholder Novo Holdings.
Novo Nordisk Says European Medicines Agency Recommends Approval of Hemophilia Treatment
The European Medicines Agency's Committee For Medicinal Products For Human Use Has Adopted A Positive Opinion, Recommending Approval Of Novo Nordisk's Alhemo (Concizumab) As The First Once-Daily Subcutaneous Prophylactic Treatment For People Aged 12...
Consumer groups are requesting the FTC in the usa to block Novo Holdings' acquisition of catalent.
According to Reuters on October 18th, consumer groups and two major unions in the USA urged the Federal Trade Commission (FTC) to block the acquisition contract of drug manufacturer Catalent by Novo Nordisk A/S's shareholder Novo Holdings, stating that the deal threatens competition in the weight loss and cutting-edge genetic therapy areas. The Public Interest Research Group, Service Employees International Union (SEIU), and other organizations expressed concerns about this $16.5 billion deal in a letter to the FTC. Last week, Democratic Senator Warren also called on the FTC to closely monitor this transaction, citing similar reasons.
Jim Cramer Says Novo Nordisk A/S (NVO) 'Doesn't Hold A Candle To Eli Lilly'
Consumer, Labor Groups Urge FTC to Block Catalent Sale to Novo Nordisk - Report
Behind the Scenes of Novo Nordisk's Latest Options Trends
BMO Capital Maintains Novo-Nordisk A/S(NVO.US) With Buy Rating, Cuts Target Price to $156
Novo Nordisk's Weight Loss Drug Ozempic Associated With Reduced Opioid, Alcohol Use Disorder Incidences, Study Shows